Friday, May 27, 2016
BioPharma Services USA has been awarded a five-year, $20 million contract with the Center for Drug Evaluation and Research (CDER), a division of the FDA. The contract is to conduct in vivo studies of generic drug products in human subjects over a period of five years, from 2016 through to 2021.
PSI, a global full-service CRO, is opening a new office in Durham, North Carolina, in the region known as Research Triangle Park (RTP). The new office is in addition to the PSI operational offices in King of Prussia, Pennsylvania, and San Francisco, California.
Worldwide Clinical Trials has opened a new, larger depot site in St. Petersburg, Russia. The new facility—at 1,300 square meters in size—allows for the storage and distribution of a wide range of clinical trial materials with special requirements and conditions for storage, as well as distribution. The new location is one of several Worldwide Clinical Trials depots located in Russia, Georgia and Ukraine.
Precision for Medicine, part of the Precision Medicine Group, has acquired Applied Immunology, which focuses in the creation and delivery of custom cell-based and immunoassay solutions. Applied Immunology supports innovative and targeted therapeutics developers across all areas, ranging from immuno-oncology to rare diseases to biosimilars from research to post-approval. Applied Immunology’s client base includes some of the most pioneering new venture-backed startups, along with many major global pharmaceutical firms.
Veristat, a full service CRO, is expanding its clinical research offerings into Europe through the acquisition of U.K.-based CRO Spero Oncology. Spero Oncology specializes in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the acquisition of Spero Oncology, Veristat now offers its clients full clinical operations support in Europe including feasibility studies, legal representation in the European Union, clinical monitoring, project management, protocol writing and regulatory strategy.